Enlivex Therapeutics Ltd.

Biotechnology • Healthcare • Ness Ziona, Israel • ENLV (NCM)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

972 2 620 8072 14 Einstein Street, Israel

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Enlivex Therapeutics Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

StocksToTrade • Dec 27

EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Yahoo Finance

Yahoo Finance • Nov 24

Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daytona Beach News-Journal

Daytona Beach News-Journal • Dec 7

Enlivex stock gains on upbeat 6-month results in knee osteoarthritis trial (ENLV:NASDAQ) - Seeking Alpha

Seeking Alpha • Nov 24

Enlivex (Nasdaq: ENLV) raises $212M to launch RAIN prediction markets treasury plan - Stock Titan

Stock Titan • Nov 24

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Enlivex Therapeutics Ltd. had layoffs?

No layoff events have been recorded for Enlivex Therapeutics Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

What industry is Enlivex Therapeutics Ltd. in?

Enlivex Therapeutics Ltd. operates in the Biotechnology industry, within the Healthcare sector.

Is Enlivex Therapeutics Ltd. a publicly traded company?

Yes, Enlivex Therapeutics Ltd. is publicly traded under the ticker symbol ENLV on the NCM. The company has a market capitalization of approximately $0.18 billion.

Where is Enlivex Therapeutics Ltd. headquartered?

Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel at 14 Einstein Street, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.